http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
알츠하이머병 치매 환자에서 도네페질(Donepezil)에 대한 최초 투약군과 전환군 간의 임상적 효용 비교 평가 : 12개월 추적관찰 연구
강효신(Hyo Shin Kang),안인숙(Inn Sook Ahn),윤지혜(Ji Hae Yun),문유진(Yu Jin Moon),황태영(Tae Young Hwang),이영민(Young Min Lee),김혜란(Hyeran Kim),정재원(Jae Won Chung),김도관(Doh Kwan Kim) 대한노인정신의학회 2010 노인정신의학 Vol.14 No.2
Objectives : The purpose of this study was to compare the efficacy between switching patients with Alzheimer's disease (AD) from galantamine or rivastigmine to donepezil because they were not responding adequately, and naive patients with AD who initiated therapy with donepezil. Methods : A total of 108 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients' activities of daily living using Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL);behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results : 86 naive patients and 22 switching patients were enrolled in the study. 74 patients completed the study and 34 discontinued their treatment before week 52. There was no significant difference between two patient groups in demographic data, baseline characteristics and dementia severity except duration of illness. The total ADAS-cog-K scores were not significantly different from baseline after 52 weeks of treatment in both groups. Both groups demonstrated deterioration of S-ADL and S-IADL at 52 weeks. The NPI scores did not significantly change in both groups. Based on the operational criteria, 61.6% of the naive group and 54.5% of the switching group were responders to donepezil. Conclusion : The switching group had similar levels of efficacy with the naive group who initiated therapy with donepezil. These results suggest that patients not responding adequately to rivastigmine or galantamine may improve or stabilize after switching to donepezil and prior medication does not effect donepezil's efficacy.
순수 알츠하이머병 치매 환자군과 혼합성 치매 환자군에서 12개월간의 도네페질(Donepezil) 투여에 따른 치료 성적의 비교 평가
강효신(Hyo Shin Kang),안인숙(Inn Sook Ahn),윤지혜(Ji Hae Yun),문유진(Yu Jin Moon),황태영(Tae Young Hwang),이영민(Young Min Lee),김혜란(Hyeran Kim),정재원(Jae Won Chung),김도관(Doh Kwan Kim) 대한노인정신의학회 2010 노인정신의학 Vol.14 No.1
Objectives:The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 12-month trial. Methods:A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured using Alzheimer’s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients’ activities of daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL);behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks, 39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change during the first six-month clinical trial. Results:84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF) analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, SIADL and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil. Conclusion:MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups. These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.
갈란타민(Galantamine) 투여 후 순수 알츠하이머병 치매와 혼합성 치매 환자의 주의력, 일상생활능력 및 신경정신행동 증상에 대한 효과 평가
강효신(Hyo Shin Kang),윤지혜(Ji Hae Yun),안인숙(Inn Sook Ahn),문유진(Yu Jin Moon),황태영(Tae Young Hwang),이영민(Young Min Lee),김혜란(Hyeran Kim),김도관(Doh Kwan Kim) 대한노인정신의학회 2012 노인정신의학 Vol.16 No.1
Objectives:The purpose of this study was to compare the efficacy of galantamine treatment, especially attention ability between patients with pure Alzheimer’s disease (AD) and Mixed dementia (MD) during a 24-week trial. Methods:A total of 40 patients were recruited for this 24-week study. The effect of galantamine on attention was measured using Seoul Computerized NeuroCognitive Function Test (SCNT) and frontal functions test of Seoul Neuropsychological Screening Battery (SNSB). Patients’activities of daily living using the Seoul-Activities of Daily Living (S-ADL) and the Seoul-Instrumental Activities of Daily Living (S-IADL) ; behavioral symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline and 24-week. Results:17 pure AD patients and 23 MD patients were analyzed in this study. Attention as measured by SCNT was not significantly different from baseline after 24 weeks of treatment in both groups. There was no significant difference between two groups in mean change from baseline in the SCNT, S-ADL, S-IADL and K-NPI scores at 24-week. Conclusion:Galantamine showed a therapeutic effect on cognition, activities of daily living, neuropsychiatric symptoms in pure AD and MD. Furthermore, Galantamine may specifically help to maintain attention and it may have positive effects on other cognitive and functional abilities.
장기원(Ki Won Jang),김지혜(Ji-Hae Kim),안인숙(Inn-Sook Ahn),김도관(Doh Kwan Kim) 대한노인정신의학회 2009 노인정신의학 Vol.13 No.2
Objectives : Our study investigated the behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) patients with three groups (mild, moderate, severe) and prevalence of BPSD with the severity of AD. Method : In a study group of 338 patients with AD (mild : 184, moderate : 99, severe : 55), information on gender, age, education was collected. The severity of dementia was measured by the Korean version of mini-mental status examination (K-MMSE) and Clinical dementia rating (CDR). The Korean version of Neruopsychiatric Inventory (K-NPI) was administered to all patients. Results : Depression/dysphoria, apathy/indifference, irritability/lability, anxiety were frequent in the mild AD group. Apathy/indifference, Depression/dysphoria, agitation/aggression, delusion were frequent in the moderate AD group. Apathy/indifference, agitation/aggression, aberrant motor behavior, nighttime behavior, anxiety were frequent in the severe AD group. Conclusion : These observations suggest that delusion was a more dominant symptom in moderate AD group and the prevalence of depression declined in severe AD group.
치매 환자 보호자의 부양 부담에 영향을 미치는 요인 탐색
안인숙,김지혜,구형모,김도관 大韓神經精神醫學會 2005 신경정신의학 Vol.44 No.4
Objectives : The purpose of this study was to examine the determinants of care burden of caregivers in patients with dementia. Methods : 128 dementia patients and patients' caregivers participated in this study. Care burden using the BI ; cognition using the K-MMSE ; dementia severity using the CDR ; activities of daily living using the S-ADL and the S-IADL ; behavior problems using NPI were measured. Results : The results showed that care burden was related significantly with the K-MMSE, the CDR, the S-ADL, the S-IADL and the NPI total score. Of the behavior problems, agitation/aggression, anxiety, disinhibition, irritability, and aberrant behavior correlated positively with care burden of caregivers. Regression analysis indicated that agitation/aggression, anxiety, the CDR contributed to care burden. Conclusion : Agitation/aggression, anxiety and dementia severity contributed to care burden of caregivers. The identified determinants of care burden and the stress of caregivers suggest areas of therapeutic intervention to reduce caregiver's burden so that the institutionalization can be delayed.
경도인지장애(Mild Cognitive Impairment)에서 단축형 Samsung Dementia Questionnaire(S-SDQ)의 임상적 유용성
윤지혜,김지혜,안인숙,정재원,송미선,김도관 大韓神經精神醫學會 2007 신경정신의학 Vol.46 No.5
Objuctives : Clinical utility of the Short Form of the Samsung Dementia Questionnaire (S-SDQ) as a screening instrument for Mild Cognitive Impairment (MCI). Methods : Three groups (n=27, Subjective Memory Impairment (SMI); n=41 MCI; n=79, Early Alzheimer's Di-sease(AD)) recruited from memory clinic were administered a battery of neuropsychological tests including S-SDQ and Korean version-Mini Mental State Examination (K.-MMSE). Results : S-SDQ, unlike the K-MMSE, had no association with the age and education ofthe subjects. Scores of S-SDQ was found to correlate (r=-.496) with scores of K-MMSE. Result of Receiver Operating Characteristic (ROC) analysis revealed that S-SDQ discriminated between the SMI and the MCI groups. Conclusion : S-SDQ may be a solution to the problem of contamination by education and age which affect traditional Cognitive screening instruments like K-MMSE, and it may be a useful tool for screening MCI.